FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2985941179> ?p ?o ?g. }

• W2985941179 endingPage "1084" @default.
• W2985941179 startingPage "1084" @default.
• W2985941179 abstract "Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening emergency caused by auto-antibodies against ADAMTS13. Current standard therapy utilizes plasma exchange (PLEX) and corticosteroids. Although this induces remission, disease relapse remains a common problem. Since more than 90% of aTTP is caused by an antibody to ADAMTS13, additional immunosuppressive therapy with rituximab (RTX) given upfront has been shown to lower relapse rates. An alternative therapy, Cyclophosphamide (CTX) has been used in relapsed disease, but data on its use in upfront management is limited to case reports only. Our study aims to compare outcomes at our institution between upfront CTX, RTX, and standard therapy alone. Our secondary objective is to identify initial presenting features that are predictive of higher relapse risk. Methods: In a retrospective cohort study, we identified all patients at our institution with a diagnosis code of TTP (ICD 9, 10: 446.6, M31.1) between 2009 and 2019. We only included patients with a confirmed diagnosis of aTTP, defined as having an ADAMTS13 level <10%, and either a positive ADAMTS13 inhibitor or antibody. We excluded patients with follow-up of less than 30 days, or thrombotic microangiopathy (TMA) due to other causes. Relapse was defined as recurrence of TMA in addition to an ADAMTS13 level <10%, or laboratory relapse evidenced as an acute drop of ADATMS13 level with a positive inhibitor with/without TMA. Time to first relapse was measured from the onset of remission, defined as the time of normalization of both platelets and lactate dehydrogenase (LDH) for at least 48 hours, until the time of relapse. The cumulative incidence of relapse (CIR) was estimated using Kaplan-Meier method, and its difference among treatment groups was examined by log-rank test. The effect of continuous and categorical covariates on relapse rate was estimated by univariate Cox model. The association of categorical variables was examined using chi-square test and the difference of continuous measurements among groups was tested using T-test or ANOVA. Results: A total of 42 patients with a diagnosis of aTTP were identified in our cohort. The average age at diagnosis was 43.7 years. All patients received standard therapy with PLEX and steroids upon initial diagnosis. The prophylaxis group (n=29) received additional upfront therapy with either RTX (n=22) or CTX (n=6), and the control group (n=12) was treated with PLEX and steroids alone. There were no significant differences in the baseline characteristics between both groups. The median time to first relapse was 34.9 months in the control group, and 108.3 months in the prophylaxis group. Treatment with standard therapy alone was associated with a multi-variate hazard risk of 6.38 (95% CI: 1.1-37.7, p<0.05) for time to initial relapse. CIR at 2, 4, and 8 years was higher in the control group (41.7%, 53.3%, and 68.8%) as compared to the prophylaxis group (31.3%, 43.8%, and 43.8%, respectively). No difference was noted in CIR with CTX versus RTX, which was 40% at 4 years with CTX compared to 47% with RTX, p = 0.97 (Figure 1). Similarly, no statistically significant difference was noted in the time to first remission between CTX and RTX treatment (18 days in with CTX versus 14.9 days with RTX, p=0.583). Inhibitor titer at diagnosis correlated inversely with duration of remission (HR: 1.29, 95% CI: 1.03-1.61, p<0.05). Initial presenting platelet count, peak LDH value or co-existing autoimmune disease were not predictive of the duration of remission. Conclusion: Our study is the first to examine outcomes in a subset of patients treated with upfront CTX therapy for initial aTTP, and suggests similar time to first remission and 4-year CIR as compared to RTX. Our institutional experience suggests that CTX may be considered as an alternative therapy in patients intolerant to RTX. However, given the small group of patients treated with CTX, larger, prospective studies are warranted to confirm this observation. Consistent with currently published literature, PLEX and steroid therapy alone was associated with a significantly shorter duration of remission compared to additional immunosuppressive therapy. Furthermore, higher inhibitor titers were predictive of a shorter duration of remission, suggesting a role for aggressive upfront immunosuppressive treatment in these patients. Disclosures No relevant conflicts of interest to declare." @default.
• W2985941179 created "2019-11-22" @default.
• W2985941179 creator A5006883756 @default.
• W2985941179 creator A5016067328 @default.
• W2985941179 creator A5033123441 @default.
• W2985941179 creator A5050265687 @default.
• W2985941179 creator A5056134287 @default.
• W2985941179 creator A5066630966 @default.
• W2985941179 date "2019-11-13" @default.
• W2985941179 modified "2023-09-27" @default.
• W2985941179 title "Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura" @default.
• W2985941179 doi "https://doi.org/10.1182/blood-2019-123537" @default.
• W2985941179 hasPublicationYear "2019" @default.
• W2985941179 type Work @default.
• W2985941179 sameAs 2985941179 @default.
• W2985941179 citedByCount "0" @default.
• W2985941179 crossrefType "journal-article" @default.
• W2985941179 hasAuthorship W2985941179A5006883756 @default.
• W2985941179 hasAuthorship W2985941179A5016067328 @default.
• W2985941179 hasAuthorship W2985941179A5033123441 @default.
• W2985941179 hasAuthorship W2985941179A5050265687 @default.
• W2985941179 hasAuthorship W2985941179A5056134287 @default.
• W2985941179 hasAuthorship W2985941179A5066630966 @default.
• W2985941179 hasConcept C126322002 @default.
• W2985941179 hasConcept C167135981 @default.
• W2985941179 hasConcept C203014093 @default.
• W2985941179 hasConcept C2776694085 @default.
• W2985941179 hasConcept C2776755627 @default.
• W2985941179 hasConcept C2777878052 @default.
• W2985941179 hasConcept C2778585876 @default.
• W2985941179 hasConcept C2779134260 @default.
• W2985941179 hasConcept C2779338263 @default.
• W2985941179 hasConcept C2780653079 @default.
• W2985941179 hasConcept C2780921031 @default.
• W2985941179 hasConcept C71924100 @default.
• W2985941179 hasConcept C89560881 @default.
• W2985941179 hasConcept C90924648 @default.
• W2985941179 hasConceptScore W2985941179C126322002 @default.
• W2985941179 hasConceptScore W2985941179C167135981 @default.
• W2985941179 hasConceptScore W2985941179C203014093 @default.
• W2985941179 hasConceptScore W2985941179C2776694085 @default.
• W2985941179 hasConceptScore W2985941179C2776755627 @default.
• W2985941179 hasConceptScore W2985941179C2777878052 @default.
• W2985941179 hasConceptScore W2985941179C2778585876 @default.
• W2985941179 hasConceptScore W2985941179C2779134260 @default.
• W2985941179 hasConceptScore W2985941179C2779338263 @default.
• W2985941179 hasConceptScore W2985941179C2780653079 @default.
• W2985941179 hasConceptScore W2985941179C2780921031 @default.
• W2985941179 hasConceptScore W2985941179C71924100 @default.
• W2985941179 hasConceptScore W2985941179C89560881 @default.
• W2985941179 hasConceptScore W2985941179C90924648 @default.
• W2985941179 hasIssue "Supplement_1" @default.
• W2985941179 hasLocation W29859411791 @default.
• W2985941179 hasOpenAccess W2985941179 @default.
• W2985941179 hasPrimaryLocation W29859411791 @default.
• W2985941179 hasRelatedWork W1566884808 @default.
• W2985941179 hasRelatedWork W2034553419 @default.
• W2985941179 hasRelatedWork W2124400226 @default.
• W2985941179 hasRelatedWork W2946198964 @default.
• W2985941179 hasRelatedWork W3033753898 @default.
• W2985941179 hasRelatedWork W3037949192 @default.
• W2985941179 hasRelatedWork W3104949179 @default.
• W2985941179 hasRelatedWork W3159566231 @default.
• W2985941179 hasRelatedWork W4234875595 @default.
• W2985941179 hasRelatedWork W2036500077 @default.
• W2985941179 hasVolume "134" @default.
• W2985941179 isParatext "false" @default.
• W2985941179 isRetracted "false" @default.
• W2985941179 magId "2985941179" @default.
• W2985941179 workType "article" @default.